MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has completed delivery of a US$1 million ArtemiC™ order to US distribution partner AMC Holdings – the largest order delivered by the company to date.
AMC Holdings recently opted to amend the terms of the US$1 million ArtemiC deal, deciding to have the product delivered in one large shipment for immediate supply in the US due to increasing demand.
ArtemiC is a supplement targeted at reducing inflammation factors and has been shown to reduce the effects of COVID-19 in 91% of patients in a peer-reviewed research paper.
The paper concluded that "ArtemiC curbed deterioration, possibly by limiting the cytokine storm of COVID-19, and bears great promise for COVID-19 patients, particularly in those with comorbidities”.
The treatment is one of the few post-COVID-19 therapies currently available, meaning it has great potential to capture a large market share should the treatment prove effective and popular.
Natural, plant-based, clinically tested
“AMC is excited to bring the first commercial order of ArtemiC into the US,” AMC Holdings general counsel Brent Yessin said.
“It will be available both online and through independent pharmacies. Since the pandemic, the federal government has stopped paying for many treatments the cost burden has shifted to the individual states and to consumers.
“With this change in policy, AMC is pleased to be in a position to offer the market a natural, plant-based and clinically tested treatment option.”